Skip to main content
Clinical Trials/JPRN-UMIN000016782
JPRN-UMIN000016782
Completed
未知

An exploratory study of treatment sensitivity and prognostic factors in a Phase III, randomized, controlled study comparing the efficacy and safety of mFOLFOX6 + bevacizumab therapy vs. mFOLFOX6 + panitumumab therapy in patients with chemotherapy-naïve wild-type RAS(KRAS/NRAS) unresectable advanced or recurrent colorectal cancer - Exploratory analysis of biomarkers in PARADIGM study

Takeda Pharmaceutical Company Limited0 sites757 target enrollmentMarch 23, 2015

Overview

Phase
未知
Intervention
Not specified
Conditions
colorectal cancer
Sponsor
Takeda Pharmaceutical Company Limited
Enrollment
757
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

A

Registry
who.int
Start Date
March 23, 2015
End Date
February 28, 2022
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • (1\)Patients who are determined by the investigator or researchers to be not suitable for participating in the additional study

Outcomes

Primary Outcomes

Not specified

Similar Trials